Tirzepatide represents a significant evolution in peptide research — a dual agonist that binds both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism distinguishes it from single-receptor peptides like Semaglutide.
This article explores the rationale behind dual agonism, the structural engineering that allows a single peptide to activate two receptor pathways, and how this differs from co-administration of two separate compounds.
Research implications:
- Simultaneous GIP and GLP-1 pathway activation
- Potential additive or synergistic effects observed in studies
- Implications for glucose and appetite research models
For research purposes only. Not for human consumption.